Verve Therapeutics (NASDAQ:VERV) Stock Price Expected to Rise, HC Wainwright Analyst Says

Verve Therapeutics (NASDAQ:VERV - Free Report) had its price objective upped by HC Wainwright from $14.00 to $15.00 in a research note released on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the stock. William Blair reaffirmed an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Royal Bank of Canada lowered their target price on shares of Verve Therapeutics from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Verve Therapeutics has an average rating of "Buy" and a consensus target price of $25.50.

Verve Therapeutics Stock Down 0.8 %

NASDAQ:VERV traded down $0.05 during midday trading on Friday, reaching $6.12. The stock had a trading volume of 1,497,833 shares, compared to its average volume of 1,553,176. The stock has a market cap of $518.14 million, a P/E ratio of -2.49 and a beta of 1.74. The firm has a fifty day simple moving average of $6.91 and a two-hundred day simple moving average of $6.03. Verve Therapeutics has a 12-month low of $4.30 and a 12-month high of $16.05.

Remove Ads

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. On average, sell-side analysts anticipate that Verve Therapeutics will post -2.49 earnings per share for the current fiscal year.

Institutional Trading of Verve Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VERV. GAMMA Investing LLC increased its stake in shares of Verve Therapeutics by 189.7% during the 4th quarter. GAMMA Investing LLC now owns 6,054 shares of the company's stock worth $34,000 after purchasing an additional 3,964 shares in the last quarter. IFP Advisors Inc increased its position in Verve Therapeutics by 823,700.0% during the fourth quarter. IFP Advisors Inc now owns 8,238 shares of the company's stock worth $47,000 after buying an additional 8,237 shares in the last quarter. Creative Planning acquired a new position in shares of Verve Therapeutics in the third quarter worth $50,000. BNP Paribas Financial Markets purchased a new stake in shares of Verve Therapeutics in the fourth quarter valued at $50,000. Finally, PFG Investments LLC acquired a new stake in shares of Verve Therapeutics during the third quarter valued at $53,000. Hedge funds and other institutional investors own 97.11% of the company's stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.